Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: EXCRETION Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride

NCT02263547
View directory record Official record
Conditions
Teriflunomide Elimination, Healthy Volunteers
Interventions
teriflunomide, Colestipol
Drug
Lead sponsor
Derrick Scott Robertson
Other
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Phase 1 Interventional

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

NCT01026415
View directory record Official record
Conditions
Carcinomas, Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin, Neoplasms
Interventions
brentuximab vedotin, rifampin, midazolam, ketoconazole
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
6
States / cities
Duarte, California • Denver, Colorado • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria

NCT02289755
View directory record Official record
Conditions
Hyperoxaluria, Nephrolithiasis
Interventions
ALLN-177
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Indianapolis, Indiana • Lake Success, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease

NCT00296400
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Rosuvastatin, Atorvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
23
States / cities
Avondale, Arizona • Phoenix, Arizona • Pasadena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body

NCT02110342
View directory record Official record
Conditions
Healthy
Interventions
[14C] PF-04449913
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Identification to Elimination in HCV-Infected Individuals

NCT03195205
View directory record Official record
Conditions
Hepatitis C
Interventions
OraQuick HCV Rapid Antibody Test
Diagnostic Test
Lead sponsor
TruCare Internal Medicine & Infectious Disease
Other
Eligibility
18 Years and older
Enrollment
3,051 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
DuBois, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

NCT04898101
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acalabrutinib, Microtracer [14C]ACP-196
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-1211 IV/Oral Mass Balance Study

NCT01702194
View directory record Official record
Conditions
OIC
Interventions
TD-1211 IV [C14], TD-1211 PO [C14]
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Oral Probiotics to Reduce Urinary Oxalate Excretion

NCT00587041
View directory record Official record
Conditions
Nephrolithiasis, Hyperoxaluria, Crohn's Disease
Interventions
Oxadrop, Agri-King Synbiotic (AKSB), Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study To Understand How Radiolabeled MK-5475 Is Taken Up By The Body, Broken Down And Then Removed From The Body in Healthy Participants (MK-5475-011)

NCT06777602
View directory record Official record
Conditions
Healthy
Interventions
[14C] MK-5475
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 19, 2026, 4:40 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How ASP3082 is Processed in Healthy Men

NCT07773129
View directory record Official record
Conditions
Healthy Volunteer
Interventions
14C-labeled ASP3082
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Not applicable Interventional

Safely Disposing of Surplus Prescription Opioids

NCT03855241
View directory record Official record
Conditions
Opioid Use
Interventions
Informational Sheet, DisposeRx Drug Disposal kit
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers

NCT01821066
View directory record Official record
Conditions
Healthy
Interventions
PD-0332991 alone, Tamoxifen 60 mg, Tamoxifen 20 mg, PD-0332991 combination
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants

NCT05050682
View directory record Official record
Conditions
Healthy
Interventions
PF-07304814
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Galeterone

NCT02729376
View directory record Official record
Conditions
Healthy
Interventions
galeterone
Drug
Lead sponsor
LTN PHARMACEUTICALS, INC.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Stress, Salt Excretion, and Nighttime Blood Pressure

NCT03636490
View directory record Official record
Conditions
Blood Pressure, Psychological Stress
Interventions
Psychological Stress Intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older
Enrollment
323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 19, 2026, 4:40 PM EDT
Recruiting Phase 3 Interventional

Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy

NCT07629635
View directory record Official record
Conditions
Migraine Disease, Patent Foramen Ovale
Interventions
Prasugrel 5mg, Transcatheter Closure of Patent Foramen Ovale
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers

NCT01711762
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0973
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vascepa to Accelerate Lipoprotein Uptake and Elimination

NCT03885661
View directory record Official record
Conditions
Lipid Disorder, Triglycerides High, Dyslipidemias
Interventions
Icosapent Ethyl 1000 MG [Vascepa]
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Human AME Study for Omaveloxolone

NCT03931590
View directory record Official record
Conditions
Healthy Male Subjects
Interventions
[14C]-Omaveloxolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Early Phase 1 Interventional

Study of Sodium Bicarbonate in Kidney Transplant Recipients

NCT01225796
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Sodium bicarbonate
Drug
Lead sponsor
University of Utah
Other
Eligibility
21 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Not applicable Interventional

Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol

NCT02260167
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
A mix of natural treatments and medications
Other
Lead sponsor
Practitioners Alliance Network
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Kailua, Hawaii
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Metabolite Identification, Mass Balance, and PK Study of [14C]-Asimadoline to Healthy Adult Male Volunteers

NCT01380561
View directory record Official record
Conditions
Healthy
Interventions
asimadoline
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
18 Years to 56 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2011 · Synced Oct 19, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects

NCT01503866
View directory record Official record
Conditions
Healthy
Interventions
bardoxolone methyl
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 19, 2026, 4:40 PM EDT